ImmunityBio’s Record Revenue Meets Mounting Legal Pressure

ImmunityBio’s stock is navigating a volatile path, caught between explosive commercial growth for its bladder cancer drug and a rising tide of shareholder litigation. The biotech firm’s first-quarter 2026 preliminary net product revenue of $44.2 million marks a staggering 168% year-over-year increase, yet this financial milestone is shadowed by legal actions stemming from a regulatory misstep.

The company’s legal troubles originated with a U.S. Food and Drug Administration warning letter made public on March 24, 2026. The FDA’s communication, dated March 13 and addressed directly to CEO Richard Adcock, cited a promotional podcast and a television advertisement for the drug ANKTIVA. The agency stated these materials created a misleading impression that the therapy could cure or prevent all cancers, claims not supported by scientific evidence. This disclosure triggered a single-day stock plunge of over 21%, erasing approximately $2 billion in market capitalization.

In response, ImmunityBio filed a detailed corrective action plan with the FDA on April 6. The company removed the cited podcast, confirmed the criticized TV commercial had never aired, and pledged to implement stricter internal review processes. This was not the first regulatory notice; the FDA had sent similar warnings to the company’s Altor BioScience subsidiary in September 2025 and January 2026.

Despite the controversy, the underlying business shows remarkable strength. The Q1 2026 revenue of $44.2 million also represents a 15% sequential increase over Q4 2025. For context, the company’s full-year 2025 revenue reached $113 million, a 700% surge from 2024. ImmunityBio ended the recent period with a robust cash position of $380.9 million in liquidity reserves.

Should investors sell immediately? Or is it worth buying ImmunityBio?

On the regulatory front, ANKTIVA is now approved in five regulatory regions encompassing roughly 34 countries. The pivotal BCG-naïve CIS study, QUILT-2.005, is fully enrolled, and a supplemental biologics license application is slated for submission later in 2026. The FDA has requested additional efficacy and long-term data for this application but did not mandate new clinical trials.

The legal landscape, however, is intensifying. Multiple law firms, including Kaplan Fox & Kilsheimer, Kahn Swick & Foti, Pomerantz, Kessler Topaz Meltzer & Check, and Faruqi & Faruqi, have initiated or joined class action suits. They allege federal securities law violations, claiming the company withheld material information. The deadline for investors to seek lead plaintiff status is May 26, 2026.

Trading recently at $7.47, the stock has recovered some ground since its March collapse, posting a daily gain of about 7% on Thursday. Year-to-date, the equity is still up more than 267%, having traded between $1.83 and $12.43 over the past 52 weeks. The coming weeks will see a critical convergence: the formation of the class action lawsuit by the May deadline and the ongoing FDA review of the company’s corrective submissions and supplemental drug application data.